is know about this subject! We do not by any means suggest that soft-tissue placentography should be used routinely, but emphasize, with figures to support it, that it can play a big part in the improving results from expectant management of antepartum heemorrhage. It can play an even bigger part in diagnosing placenta previa before the patient has bled.
Dr. Blair Hartley, also in reply, pointed out that he had begun his paper by assuming that nobody present ever sent a pregnant woman for X-ray examination "unless there be good medical or clinical reason for doing so."
It was useless to admonish the radiologist or to denigrate his art when it was the obstetrician and not the radiologist who referred the cases about which the whole discussion had centred.
Which opinion carried more weight regarding radiography in placentography? That of the man who had really tried it out and checked the results over four to ten years? Or that of the man who merely stood up and said that he never used the method? Furthermore, radiology not only revealed the mistakes of the radiologist, but some of those of the obstetrician-which could account in part for any "resistance" shown during the discussion towards acceptance of the X-ray method. POSTSCRIPT (15.5.59 ).-Since this discussion took place, the present position regarding radiation hazards to patients has been stated in the Interim Report of the Adrian Committee on "Radiological Hazards to Patients," published by the Stationery Office in May, 1959 . See In 1935 one of the most outstanding contributions to obstetrics and pharmacology was made by Dudley and Moir-the isolation of the alkaloid ergometrine. So often in the history of medicine what begins as an academic exercise proves itself to be of inestimable benefit to humanity. Such is the story of ergometrine and we should do honour to one, Professor Chassar Moir, who achieved this and is still in our midst. This drug has made maternity safer by reducing mortality and morbidity from haemorrhage and sepsis. At University College Obstetric Hospital we are naturally proud that it was there that he undertook much of his original work; we have been under his influence ever since this epochal discovery.
At a meeting of this Section, Flew (1947) referred to the first use of ergometrine with the birth of the baby's head when in 1935 at University College Hospital this drug was given by intramuscular injection in a consecutive series of 500 deliveries. In no case was there a constriction ring, inversion of the uterus or manual removal of the placenta. That was over twenty-five years ago and yet many women in this country are still denied this means of preventing postpartum heemorrhage. In 1951 we decided that all cases of vaginal delivery should be given intravenous ergometrine (0 5 mg.) with the crowning of the baby's head. My assistants, Martin and Dumoulin (1953) , reported 1,000 consecutive deliveries in which this treatment was given. Postpartum hemorrhage was dramatically reduced from 13X1 % (control) to 1 2% (ergometrine series). Since then we have given ergometrine intramuscularly with or without hyaluronidase with the delivery of the anterior shoulder but recently we have returned to the intravenous route. In addition the placenta is delivered by controlled cord traction (a modification of the Brandt-Andrews manceuvre).
This method has now been used in 421 unselected normal deliveries. Miss Pamela Bacon, my assistant, has found in this series that the postpartum hemorrhage and manual removal of placenta rates are identical, namely 1-4%. In 93 % of these cases the blood loss was 284 ml. (10 oz.) or less and in 83 % the third stage was completed within five minutes of the birth of the baby.
The activity of the drug using the Smyth tocograph has been investigated on the postpartum uterus. ergometrine. The tonie of the uterus is raised and contractions are almost continuous. Labrum (1955) in my clinic compared a small group of patients who were given intramuscular ergometrine with a group who were given this drug with hyaluronidase. With doses of 0X25 mg. the latent period between injection and contraction was almost halved when hyaluronidase was added and the average height of contraction was increased by 30%. He also found that with doses of 1-0 mg. the addition of hyaluronidase made little difference to the average latency, but increased the average contraction by 53 %. But with this dose there were unpleasant side-effects so we believe the optimum dose of ergometrine should be 0-5 mg.
Convinced that ergometrine should be given routinely with the birth of the baby, we have now turned our attention to its possible use in induction of premature labour in cases of intrauterine death or anencephaly by means of intravenous drip infusion. Dr. C. N. Smyth has compared its effect with Syntocinon in physiological dosage and found more tendency to produce spasm and "uterine fibrillation" with a longer duration of action. It is hoped that this treatment would activate the uterus when it is necessary to terminate pregnancy many weeks before term for reason of a dead or malformed foetus. Oxytocin infusion often fails in these early cases. In two recent cases in which there had been slight hypertension during pregnancy, the ergometrine infusion produced pressor effects. In one of these the blood pressure rose alarmingly (Fig. 2) , and there was a concomitant rise in uterine tone.
In Fig. 3 the effect of changing from ergometrine to Syntocinon infusion is observed. The blood pressure has dropped and the uterine tone and rhythm have returned to normal. We are wondering whether we have stumbled on a new "pressor test" for pregnancy toxvmia. In both the cases referred to above labour was brief and was completed on the same day as the infusion was started. In other cases there has been a similar experience.
Methyl ergometrine is supposed to have less pressor effect and perhaps should be used in toxamic patients. It has also been claimed to be twice as active as ergometrine, but Myerscough and Schild (1958) have disproved this.
It would seem that ergometrine acts by increasing the tone of the uterus and by shortening its muscle fibres. From tocographic tracings it is very obvious that this drug induces a state of "uterine fibrillation". On the other hand, Syntocinon infusion produces a rhythm of contraction and relaxation without much alteration in the tone.
Why do we make haste so slowly to apply a method which has been shown incontrovertibly to reduce the risk of postpartum hvmorrhage? It is depressing that one of my residents, now practising in the Midlands, should write recently to me thus: "The main difficulty is in persuading midwives to give ergometrine and Hyalase with the crowning of the head. They find all sorts of excuses for not giving it (hadn't got time, hadn't got a free hand, forgot in the rush). But on close questioning they will often admit that they are convinced from what they have been taught as student midwives that this procedure is wrong, and the failure to give ergometrine and Hyalase is a convenient salve to their consciences."
Finally, there is the challenge in the Report on Confidential Enquiries into Maternal Deaths in England and Wales, 1952 -1954 (Walker et al., 1957 which reveals that 113 mothers died from postpartum hiemorrhage. According to the assessors 90% of these deaths were preventable and in my o-pinion these deaths and the many "near deaths" could have been prevented by the administration of ergometrine with the birth of the baby. This practice should now be accepted as routine and obligatory in the management of labour. Perhaps in the near future those attendants who allow a mother to die from postpartum hwmorrhage because ergometrine has not been given at the right time will be considered negligent. It would seem that only by such a threat will parturient women be prevented from dying unnecessarily and be given the security they deserve.
Mr. Arnold Walker (London): Administration ofErgometrine by the Midwife
Medical treatment prescribed by any person other than a registered medical practitioner requires strict control. To a greater extent than in any other field the midwife has from time to time to undertake emergency treatment on her own responsibility in the absence of a doctor. The use of ergometrine, or in fact any other treatment carried out by a midwife in a case of postpartum hemorrhage, could never be questioned and indeed any treatment carried out in good faith as a life-saving measure would protect the midwife from professional criticism, no matter what the result of the treatment.
The use of ergometrine as a routine in normal cases is quite different and it is with this that we are now concerned.
The Central Midwives Board has the statutory duty of regulating the practice of midwives and did so in great detail when the great mass of midwives were private practitioners working in the homes of their patients and the standard of practice necessitated a close control. For a number of years, however, all but a small minority have been members of a hospital team or members of an organized domiciliary service working under vastly different conditions and under closer medical control. The rules and warning notices of the Central Midwives Board are now almost entirely administrative in character and, as regards drugs, they place no bar on the administration of any drug, provided that the midwife has been trained in the indications for the drug and is familiar with its dosage and methods of application. This general rule is qualified by special rules regarding the use of inhalational analgesics and, of course, the midwife must comply with the Dangerous Drugs Regulations. There is still one further point which does not lend itself to any form of rule and that is the administration, not as an emergency measure, of any substance which may have dangerous results even if administered under medical instructions. I refer to the use of pituitary extract when the doctor is not present. This is a subject on which we look for enlightenment at the Cardiff Congress next July. At the moment, the Central Midwives Board does not considerthat a midwife should administer pituitary extract before the uterus is empty, unless the responsible medical practitioner is immediately available.
The Central Midwives Board is an administrative body and although its composition provides expert knowledge in various fields, it is guided by what it believes to be the generally accepted views of clinicians. The use of ergometrine provided a useful example. Up to the end of the last war the most certain way of failing any midwifery examination was to advocate the administration of ergot before the uterus was empty. Ergometrine then came into general use at the end of the second stage and the Board found it necessary to write to all examiners pointing out that many pupils were being taught to use ergometrine as a routine and suggesting in polite terms that examiners should recognize this. The use of ergometrine as a routine is now widely practised by midwives and its administration by midwives is covered by the warning notice.
When we come to intravenous ergometrine we are faced with the problem of venepuncture by midwives. The Board has never said either that venepuncture is outside the province of a midwife or that midwives must be trained to perform venepuncture. The responsibility must be borne by the responsible medical practitioners and it is up to them to be satisfied that midwives who put needles into veins are competent to do so.
It is always difficult to assess statistically the value of such measures as the routine use of ergometrine at the end of labour because the great majority of cases in which it is used would behave equally well without it. I am convinced that it reduces postpartum hemorrhage. Equally important is the question of any undesirable results that may arise and this is of great significance to a body like the Central Midwives Board. I have not personally encountered complications attributable to ergometrine administered in any way. No such reports have reached the Central Midwives Board and we have found nothing in the maternal death reports since 1952 to suggest that the administration of ergometrine contributed in any way to the death of a patient.
I will end by repeating that the Central Midwives Board places no restrictions on midwives regarding the administration of ergometrine intramuscularly or intravenously, provided that the midwife knows what she is doing.
Mr. Norman Kimbeli (Peterborough):
Postpartum hiemorrhage is a potential killer and any measure which reduces the amount of blood lost after parturition decreases the mortality and the morbidity.
It is not possible for intravenous ergometrine to be given to all patients before the baby is delivered but it is possible for all women to be given intramuscular ergometrine at the same moment of election. Furthermore, some 250,000 women are delivered annually in their own homes by district midwives, and in most maternity hospitals not attached to medical schools normal deliveries are conducted by midwives. Midwives are not permitted to give intravenous injections, but intramuscular injections of ergometrine are allowed. The conventional technique in general use by midwives is to give an intramuscular injection of 0 5 mg. of ergometrineafter the placenta has been delivered or before if the hwemorrhage is excessive.
In December 1950, as the postpartum hemorrhage rate in my units was high (6 4 %), I decided to try the effect of a combination of ergometrine maleate with hyaluronidase (Hyalase) in the hope that this would enable the midwife to achieve an oxytocic effect quickly enough to allow the injection to be given after delivery of the feetal head, thus simulating an intravenous injection.
The injection is prepared by mixing 0 5 mg. of ergometrine maleate with 1,500 international and Gyncecology 569 units of Hyalase in a syringe and this is put on the delivery trolley ready for use as soon as the foetal head is delivered, the drugs being immediately injected into the lateral aspect of the patient's thigh by the attending midwife. This technique has been in continuous use for over nine years and the results we have had in the 72 beds in my units have justified its adoption (Kimbell, 1954) . Dutton (1958) has published a controlled trial using Ergo-Rondase in a selected group of 500 cases and compared the results with 707 control cases.
He found in primigravidae that the incidence of postpartum hemorrhage was significantly reduced from 6X2% to 2 5%. In his series the incidence in normal multigravidw (2-5 pregnancies) was not reduced but the severity of the bleeding was less and the average duration of the third stage in normal cases was reduced. Manual removal of the placenta was not significantly increased. Jonas (1958) has reported the results of a controlled trial of ergometrine and Hyalasethe technique being introduced in October 1954 at the City of London Maternity Hospital because of dissatisfaction with the incidence of postpartum haemorrhage, which had been 6-1 % over the first nine months of 1954. Over this same period of time the manual removal rate was 1 *76%. He reported that the incidence of postpartum hwmorrhage was reduced to 2-38% and the manual removal of the placenta rate to 1I3 % (Table I ).
In July 1954 I introduced the Brandt-Andrews technique of the placenta after reading de Lee and Greenhill (1947) on the subject. The technique, very briefly, consists of applying an artery forceps to the umbilical cord as close to the vulva as possible, and while maintaining steady continuous traction on the cord the left hand of the accoucheur is placed on the abdomen of the mother, and by gently pushing the anterior surface of the uterus upwards towards the patient's umbilicus the cord is found to elongate tThis difference is statistically significant. I if the placenta has separated; if it has not, the cord will not descend.
Nine midwives working in my units for the past two years have kindly given me their individual results (Table II) . They had, between survey, 1957-1958 (Kimbell, 1958) them, delivered consecutively 1,349 mothers: all had been given intramuscular ergometrine and Hyalase after delivery of the baby's head. They failed to deliver the placenta in 13 additional patients and these required manual removal of the placenta. Only 11 patients out of 1,264 whose placenta were delivered by the Brandt-Andrews technique had himorrhages of 20 oz. or more. In 85 patients fundal pressure was used to deliver the placenta because the Brandt-Andrews technique failed-this occurred chiefly at the beginning of the adoption of the Brandt-Andrews method when midwives exerted too much traction on the cord, which began to tear, so fundal pressure was used. The average blood loss in these cases was 3 oz. and the average time for delivering the placenta was four minutes (excluding postpartum htmorrhage cases and manual removal cases). The point I wish to make is that all these 1,349 women could have been delivered by these midwives in domiciliary practice.
No cases of acute inversion of the uterus have occurred since the adoption of the Brandt-Andrews technique. The use of ergometrine before delivery of the baby has produced firm tone in the uterus and thus prevented the atonicity which is an essential prerequisite before inversion can begin.
In all cases delivered in the Peterborough Group of Hospitals ergometrine maleate is given; if a doctor is present, the intravenous route is chosen; if a midwife, the intramuscular technique with Hyalase.
In 1954, Russell and others published an article on intravenous ergometrine given with the anterior shoulder and the undiagnosed second twin, giving details of 4 patients and suggesting that the death of one of the babies might, at least in part, have been caused by the strong uterine contractions which followed the administration of ergometrine. As the result of their experience the authors felt that, in similar cases, conservation of the second sac of membranes until immediate delivery of the second twin could be carried out under aniesthesia would do much to prevent interference with the placental circulation. Kurtz et al. (1955) reviewed 500 consecutive twin deliveries. They found that oxytocic drugs were given in 68 cases of undiagnosed twins after the partial birth of the first twin-two second twins died. On the other hand an oxytocic drug was given in 136 cases after the second twin delivery but before the placenta was expelled, and of these 136 cases 14 were lost. They concluded that their results seemed to indicate that oxytocic drugs even when mistakenly administered too soon have no deleterious effect upon the second twin. Labrum (1955) investigated by external abdominal tocograph the effect of hyaluronidase when given intramuscularly in combination with ergometrine maleate in a small series of 22 puerperal patients, giving the injections on the second and third day after delivery. He concluded that the action of hyaluronidase should enable the midwife using intramuscular injections to get results almost as good as those obtained by the doctor with intravenous injections. Embrey and Garrett (1958) reported results using a tocograph made in Oxford or an intrauterine balloon in another assessment on the additive effect of hyaluronidase when combined with ergometrine maleate and given intramuscularly to puerperal women. They compared 12 patients given the combined injection intramuscularly with 6 patients who had intravenous ergometrine, and 12 patients who were given ergometrine alone intramuscularly. They found that the injections, which were given on varying dates from the second to the eighth day of the puerperium, produced oxytocic response as follows: intravenous ergometrine 41 sec. (average time), intramuscular ergometrine plus hyaluronidase 4 min. 47 sec., and intramuscular ergometrine alone, 7 min. They found that there was good expectation that ergometrine and hyaluronidase would act within five minutes but that without hyaluronidase the latent period varied considerably. Labrum (1958) , in commenting on Embrey and Garrett's paper, agreed with the latency period but added that hyaluronidase when added to ergometrine increased the strength of the resulting uterine contraction by 30% and 50% with 0-25 mg. and 1 mg. doses of ergometrine respectively.
It is difficult for me to comment on their tThis difference is not statistically significant. (Tables-III and IV) .
Finally, Thble V shows the Peterborough results, comparing 1953-the last year in which fundal pressure was the method in use for expelling the placenta-with 1958, when the Brandt-Andrews technique was used in almost every case, ergometrine being given either intramuscularly with Hyalase, or intravenously.
In 1953 there were 1,316 deliveries with 3-1y% postpartum haemorrhage, and 2'05 % of manual removal of the placenta, while in 1958 there were 1,579 deliveries with 1 3 % of postpartum heemorrhage and 1 -27 %Y of manual removal of the placenta. The number of deliveries includes every patient except those delivered by Caesarean section.
Professor J. Chassar Moir (Oxford):
It may surprise many of us to recall that until twenty-three years ago there was no pure ergot preparation which could bring about a rapid uterine contraction when given by injection. That need was filled when ergometrine became available, and it is not surprising that this drug soon became one of the "musts" of the obstetrician's bag. Because of its reliability and freedom from side-effects it quickly displaced pituitary extract, and even the purified oxytocin, as the treatment of choice for postpartum hiemorrhage. A slightly later use was its administration during the emergence of the feetus from the birth canal in order to curtail the third stage of labour and to reduce blood loss (Davis, M. E., 1940, Amer. J. Surg., 48, 154) . For this purpose the drug has been outstandingly successful.
By contrast, attempts to use ergometrine during labour have never gained general approval because uterine contractions tend to occur in rapid succession and to persist for many minutes after the administration of the drug. Feetal asphyxia may thus be caused; and, so far as my knowledge goes, no one has yet attempted to equate a dilute ergometrine drip with a dilute Pitocin drip. Ergometrine dosage.-The new principle was isolated in pure crystalline form and its method of manufacture and characteristics first described in 1935 (Dudley, H. W., and Moir, C., 1935, Brit. med. J., i, 520). An immediate necessity was to determine the dosage which in clinical work would be both effective and safe. To this end I made many observations with a recording apparatus to determine (1) the minimum dose that would produce a significant uterine effect, (2) the maximum dose that could be given without side-effects such as nausea and dizziness. The results were reasonably consistent, and the halfway dose between the extremes mentioned seemed to be as follows: for oral administration, 1 mg.; for intramuscular injection, 0-5 mg.; for intravenous injection, 0-25 mg. I realized that a great responsibility rested on me in making these recommendations, and in particular I felt anxiety lest this new drug given by intravenous injection might, in some patients, produce unexpected results. For safety's sake I therefore recommended that the intravenous dose should be half of that already mentionedthat is, that it should be 0-125 mg.
In the years which followed, and with the availability of a purer commercial product, it became apparent that my fears were groundless and that ergometrine could be safely given intravenously in doses of 0-25 mg. or even, if slowly administered, of 0-5 mg. I cannot, however, bring myself to believe that an intravenous dose so large as 1 mg., which is the recommendation of one group of workers, is either necessary or is free from side-effects such as nausea.
Unfortunately, the very small dose originally recommended is still produced and sold in ampoules by some manufacturing firms. This is a serious mistake, for the full therapeutic effect of ergometrine will not be obtained by the use of these ampoules, which will only cause disappointment to the doctor, and danger to the patient who is suffering from postpartum himorrhage.
Another technicality must now be faced. Ergometrine was originally measured in terms of the pure base. The 1948 Pharmacopeeia, however, stipulated the use of a s'alt, namely ergometrine maleate, which contained only 74% of ergometrine base. It follows, therefore, that the intravenous dosage originally suggested will, if applied to the modern preparation, fall even shorter of the optimum amount.
Rather surprisingly, the oral dosage originally suggested has proved to be rather large, for 1 mg. of ergometrine dissolved in water will cause nausea in some people. Fortunately, this is not a serious matter, for ergometrine is 'seldom administered by mouth; and if oral medication is really desired it is probably just as satisfactory, and certainly much cheaper, to give a crude preparation of ergot such as the liquid extract which, until the last Pharmacopoeia, was an official preparation. From time to time, reports have come from the U.S.A. that administration of ergonovine (the American name for ergometrine) will sometimes cause a sharp, and even dangerous, rise in blood pressure if administered after the third stage of labour. I have never been able to understand these reports for they are quite contrary to my own experience.
Finally, I should like to touch on a method of administering ergometrine after the birth of the baby which, despite publicity by myself and others, has been strangely neglected. After the expulsion of the baby the uterus will usually be felt to impinge on the anterior abdominal wall. Now, as the bladder at this stage is also empty, it follows that a needle can be safely thrust through the abdominal wall, about 2 in. (5 cm.) below the umbilicus, to penetrate deeply into the uterine corpus. Ergometrine so injected will take effect in about one minute and the contraction will slowly spread throughout the uterine musculature. By this method there is less immediate spasm of the lower part of the upper uterine segment (so often wrongly assumed to be a spasm of the cervix uteri), and hence less o72 2a9 chance of an hour-glass contraction with retention of the placenta. This method is very simple in the majority of cases, but is not of course applicable to the obese woman or to the exceptional case in which the uterus is positioned far back in the abdomen.
Dr. M. P. Embrey: Garrett and I have recently described tocographic experiments which confirmed that hyaluronidase undoubtedly speeds the action of intramuscular ergometrine; but the gain was such (some 30 %) that, while we admitted its value as a stop-gap procedure, we questioned its routine adoption (Embrey and Garrett, 1958) . We found that hyaluronidase accelerates the action of intramuscular ergo-even with hyaluronidase the injection takes five minutes to act (Fig. 1) . It was on this chronological evidence that Garrett and I queried the superiority of the method for routine use; for we thought the speed of action of the hyaluronidase injection was disappointingly slow, while we also had in mind the difficulty of making the injection -Dutton (1958) reports 19 5% failure rateand the increased cost. On the other hand it might be argued that if intramuscular ergometrine is so slow the need for hyaluronidase is all the greater. Whatever may be its place as a routine measure, I would maintain that in the treatment of emergency heemorrhage the method falls far short of the efficacy of intravenous ergometrine. metrine (0-5 mg.) by just over two minutes. Now if intramuscular ergometrine worked in three to four minutes (Moir, 1935) , hyaluronidase would bring the speed of action of the injection down to one to two minutes-little more than that of the intravenous injection-and the gain would be very valuable indeed.
But I was surprised to find that the mean speed of action of plain intramuscular ergometrine (0 5 mg.) was seven minutes-and so Indeed, if an intravenous injection cannot be given it might be better to consider giving intramuscular oxytocin with hyaluronidase. There will doubtless be objections to my suggestion, but in a small series I have confirmed that intramuscular oxytocin (5 units) and hyaluronidase acts in just over one minute, compared with about three minutes for plain intramuscular oxytocin (Fig. 2) followed up with the longer acting ergometrine. It is sometimes thought that oxytocin, unlike ergometrine, does not produce tetanic contraction of the uterine muscle but the records reproduced illustrate that the difference is one of degree only. The larger doses of oxytocin produce well-marked, if comparatively shortlived, spasm. The apparent slowness of action of intramuscular ergometrine is difficult to understand. Professor Moir's original tracings were made with ergometrine base, whereas since the 1948 Pharmacopeeia, for the sake of stability, we have all been using ergometrine maleate. My first thought was that the addition of the maleate group to the molecule had slowed down its rate of absorption; but it does not seem to be as simple as that, and further investigation of the problem has to be undertaken.
There is one other aspect of the matter to which I would refer. Nobody would question the excellence of the results reported by Kimbell (1954) with ergometrine and hyaluronidase, but I believe the plain intramuscular ergometrine injection given with the anterior shoulder is capable of good results too. Few figures are available but some of them are not unimpressive. For example, Daley (1951) found that in primigravide the postpartum hemorrhage rate was reduced from 13 2% to 5 2%. We have been using this technique in the Nuffield Department at Oxford for several years now. I cannot give a complete analysis of the results, but in 1952 (before adopting the technique) the postpartum hemorrhage rate was 8-6%, while in 1954 (the first complete year with ergometrine technique) the incidence of postpartum heemorrhage was 2-2%.
Dr. Norman Smyth, referring to Professor Chassar Moir's remark concerning equating ergometrine with oxytocin, said he had attempted to compare the two drugs on a number of occasions by dilute intravenous infusions and had come to the conclusion that one could not produce oxytocin-like contractions, or normal labour-like contractions, with ergometrine, however dilute the infusion might be. This he believed to be because they acted on the uterus through different mechanisms, ergometrine having a true oxytocic effect on the muscle cells and oxytocin acting principally, when dilute, on the contraction-organizing mechanism which produced a uniform contraction of the whole uterus followed by a generalized relaxation. This appeared to be an effect on the transmission of the action potential between muscle fibres.
Mr. John Hanington presented figures from St. Stephen's Hospital for the postpartum himorrhage and manual removal rates from 1953 until 1958.
Ergometrine with Hyalase was first used at the birth of the anterior shoulder in June 1956.
The postpartum haemorrhage rate was reduced from 10-9% in January to May, down to 2-7% in the June-December period. There was a slight increase in the manual removal rate, from 1 5% to 21%.
1958 should be regarded as an exceptionally lucky year for the department, as the postpartum hemorrhage rate was reduced to 0 9 %.
Obviously, these figures depended to a large extent on the accuracy and judgment of the midwives, pupil midwives and medical students who undertook the normal deliveries and recorded the amount of blood loss.
His last point was that the combined injection of ergometrine and Hyalase cost ls. 7d. This was cheaper than a pint of blood.
Mr. John Sophian (London) said occasional risks might arise from the invaluable prophylactic exhibition of ergometrine, to which and to whose wtiological significance he wished to draw attention. Professor Nixon had very clearly shown that there was a rise of blood pressure accompanying the intravenous drip infusion of ergometrine used to induce early premature labour in 2 cases, more marked in the one where the fcetus was alive. Here an increased and sustained tone of the uterine muscle was intimately associated. The significance of this happening has been enlarged and underlined by 2 cases reported from Dublin (Feeney, 1959, personal communication) when in each 0 25 mg. ergometrine was intravenously administered before the delivery of the second and undiagnosed twin. Immediately following the injection there was a spasm of the uterus, with the almost immediate onset of convulsions. The second foetus perished. In one case the blood pressure previously had not exceeded 130/90 and a trace of albumin had been present in the urine; in the other the signs of toxaemia had been more marked. There can be no doubt of the causal relationship of a heightened uterine tonus with (a) the rise of blood pressure or with (b) the ensuing eclampsia. Once again the unique aetiological significane ofc the utero-renal reflex in the production of toxxemia is evident.
